Hopp til hovedinnhold
Antidepressiva kan gi bivirkninger. Den medisinen som gir minst bivirkning for deg, er ofte det riktige valget for deg.
Antidepressiva kan gi bivirkninger. Den medisinen som gir minst bivirkning for deg, er ofte det riktige valget for deg.

Antidepressiva

Antidepressiva er medikamenter som virker mot depresjon. De virker ved at de kan påvirke signalstoffer i hjernen hos personer som sliter med depresjon.

Sist revidert:
QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/psykisk-helse/legemidler/antidepressiver/ 

Hvorfor virker medisiner mot depresjon?

Valg av preparat

Virkning

Bivirkninger

Varighet

Avhengighet?

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet N06A Antidepressiver. Referanselisten for dette dokumentet vises nedenfor.

  1. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005; 143: 415-26. Annals of Internal Medicine 
  2. Spigset O, Mårtensson B. Drug treatment of depression. BMJ 1999; 318: 1188-91. British Medical Journal 
  3. Thase ME, Greenhouse JB, Frank C et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997; 54: 1009-15. PubMed 
  4. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline 23. London: NICE, 2004. www.nice.org.uk/pdf/CG023quickrefguide.pdf (accessed 6 Jan 2005).
  5. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5: e45. PubMed 
  6. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: Systematic review and meta-analysis. Arch Gen Psychiatry 2006; 63: 1217-23. PubMed 
  7. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-58. PubMed 
  8. Gunnell D, Ashby D. Antidepressants and suicide: what is the balance of benefit and harm. BMJ 2004; 329: 34-8. PubMed 
  9. Castberg I. Seponeringssyndrom etter behandling med antidepressiver. Tidsskr Nor Lægeforen 2004; 124: 2493-4. PubMed 
  10. Frost J, Sandvik P, Spigset O. Seksuelle bivirkninger av antidepressive legemidler. Tidsskr Nor Legeforen 2010; 130: 1930-1. Tidsskrift for Den norske legeforening 
  11. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160: 790-2. PubMed 
  12. Paton C, Ferrier IN. SSRIs and gastrointestinal bleeding. BMJ 2005; 331: 529-30. PubMed 
  13. De Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106-9. PubMed 
  14. Dalton SO, Johansen C, Mellemkjær L, Nørgård B, Sørensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59-64. PubMed 
  15. Renoux C, Vahey S, Dell'Aniello S, Boivin JF. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol 2016. pmid:27918771 PubMed 
  16. Venflaksine: more dangerous than most "selective" serotonergic antidepressants. Prescrire INtr 2016; 25: 96-9. pmid:27186622 PubMed 
  17. Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013; 346: f288. BMJ (DOI) 
  18. Coupland C et al. Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: Cohort study using primary care database. BMJ 2016; 352: i1350. doi:10.1136/bmj.i1350 DOI 
  19. Eyding D, Lelgemann M, Grouven U. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials . BMJ 2010; 341: c4737. BMJ (DOI) 
  20. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 5: 1-11. PubMed 
  21. Berle JØ. Behandling av svangerskapsrelatert psykisk sykdom. Tidsskr Nor Lægeforen 2003; 123: 2037-40. PubMed 
  22. Malm H, Sourander A, Gissler M, et al. Pregnancy Complications Following Prenatal Exposure to SSRIs or Maternal Psychiatric Disorders: Results From Population-Based National Register Data. Am J Psych 2015. doi:10.1176/appi.ajp.2015.14121575 DOI 
  23. Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venflaksine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ 2015. doi:http://dx.doi.org/10.1136/bmj.h1798
  24. Reefhuis J, Devine O, Friedman JM, et al. Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports. BMJ 2015; 351: h3190. doi:10.1136/bmj.h3190 DOI 
  25. Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012; 344: d8012. BMJ (DOI) 
  26. Huybrechts KF, Bateman BT, Palmsten K, et al. Antidepressant use late in pregnancy and risk of persistent hypertension of the newborn. JAMA 2015; 313: 2142-51. doi:10.1001/jama.2015.5605 DOI 
  27. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med;2009:163, 949-54.
  28. Stephansson O, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013 Jan 2; 309(1): 48-54. PubMed 
  29. Marroun HE, Jaddoe VWV, Hudziak JJ, et al. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 2012; : doi:10.1001/archgenpsychiatry.2011.2333. DOI 
  30. Rai D, Lee BK, Dalman C, et al. Parental depression, maternal antidperessant us during pregnancy, and risk of atism spectrum disorders: population based case-control study. BMJ 2014; 346: f2059. BMJ (DOI) 
  31. Handal M, Skurtveit S, Furu K, Hernandez-Diaz S, Skovlund E, Nystad W, Selmer R. Motor development in children prenatally exposed to selective serotonin reuptake inhibitors: a large population-based pregnancy cohort study. BJOG. 2015, Sep 15. doi: 10.1111/1471-0528.13582. DOI 
  32. Lunde I, Langaas HC. Vortioksetin og graviditet. RELIS 2017. relis.no